TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells

Highlights ► Imiquimod and resiquimod enhance the secretion of various proinflammatory cytokines by slanDCs. ► Imiquimod and resiquimod augment the tumor-directed cytotoxic activity of slanDCs. ► Resiquimod improves slanDC-mediated stimulation of T lymphocytes. ► Resiquimod enhances the ability of s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer letters 2013-07, Vol.335 (1), p.119-127
Hauptverfasser:	Jähnisch, Hanka, Wehner, Rebekka, Tunger, Antje, Kunze, Anja, Oehrl, Stephanie, Schäkel, Knut, Rohayem, Jacques, Bornhäuser, Martin, Tonn, Torsten, Bachmann, Michael, Schmitz, Marc
Format:	Artikel
Sprache:	eng
Schlagworte:	agonists Aminoquinolines - pharmacology Antigens Antigens, CD - metabolism Antineoplastic Agents - pharmacology Apoptosis B7-2 Antigen - metabolism Biological activity Cancer CD83 Antigen Cell Proliferation Coculture Techniques Cytokines Cytokines - metabolism Cytotoxicity Cytotoxicity, Immunologic - drug effects Dendritic cells Dendritic Cells - drug effects Dendritic Cells - immunology Dendritic Cells - metabolism Drug Screening Assays, Antitumor Hematology, Oncology and Palliative Medicine HLA-DR Antigens - metabolism HT29 Cells Humans Imidazoles - pharmacology Imiquimod Immune system Immunoglobulins - metabolism Immunomodulation - drug effects Immunotherapy Inflammation Mediators - metabolism K562 Cells Killer Cells, Natural - immunology Lymphocyte Activation Lymphocytes Melanoma Membrane Glycoproteins - metabolism natural killer cells Resiquimod Rodents Studies T-lymphocytes T-Lymphocytes - immunology therapeutics Toll-Like Receptor 7 - agonists Toll-Like Receptor 7 - metabolism Toll-Like Receptor 8 - agonists Toll-Like Receptor 8 - metabolism Tumor immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights ► Imiquimod and resiquimod enhance the secretion of various proinflammatory cytokines by slanDCs. ► Imiquimod and resiquimod augment the tumor-directed cytotoxic activity of slanDCs. ► Resiquimod improves slanDC-mediated stimulation of T lymphocytes. ► Resiquimod enhances the ability of slanDCs to activate natural killer cells. ► Imiquimod and resiquimod trigger various immunostimulatory properties of slanDCs.
ISSN:	0304-3835 1872-7980
DOI:	10.1016/j.canlet.2013.02.003